Xencor, Inc. (XNCR)

NASDAQ • Healthcare

$25.18

-$0.66 (-2.6%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$25.52

Previous Close$25.18

Day Range$24.42 - $25.81

Avg. Volume (3M)1.3M

Market Cap$1.8B

52 Week Range

$10.38$30.61

Next EarningsIn 10 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$51.2M100%

Gross Profitminus cost of goods$51.2M100%

In plain terms: out of every $100 in revenue, Xencor, Inc. currently loses $42.

Fundamentals & Financials

Revenue (TTM)

$104.9M

Net Income (TTM)

-$163.3M

EPS (TTM)

-$2.17

ROA (TTM)

-22.53%

Current Ratio

6.39

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+47.4%Q3 2025-$0.41

+88.9%Q4 2025-$0.08

+85.9%Q1 2026-$0.09

-163.1%Q2 2026-$1.71

+63.8%Q3 2026-$0.29

Nov 4

in 10 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Next report — what to expect

Xencor, Inc. (XNCR) reports on November 4, 2026. Wall Street expects EPS of -$0.35 on revenue of $59.1 million. For trailing context, revenue grew +17.5% year over year last quarter. Xencor has beaten EPS in 6 of 8 most recent quarters, so focus on updates versus those consensus marks.

View full earnings history

About Xencor, Inc.

Xencor, Inc. is a NASDAQ-listed biotechnology company that discovers and engineers monoclonal antibody and cytokine therapeutics, mainly for cancer and autoimmune disorders. In FY2025, it generated $125.6 million in revenue. Its marketed and partnered programs include Sotrovimab, Ultomiris, and Monjuvi.

Name

Xencor, Inc.

CEO

Bassil I. Dahiyat

Website

www.xencor.com

Industry

Healthcare

Year Founded

1997

Employees

260

Today's Snapshot

AI-generated

XNCR closed 2.5% below yesterday's close, in line with a weaker sector. XNCR reports earnings on 4 November.

Trading Volume

Above 10d avg 1.3M

1.4M

vs S&P 500 Today

Underperforming Market

-2.03%

Updated: October 23, 2026 at 20:11 UTC

Technical Indicators

6 Buy1 Neutral1 Sell

XNCR shows a constructive short-term picture with price sitting above its 10- and 20-period averages while longer-term 100/200-day averages remain well below, indicating an underlying bullish bias. Momentum indicators are mildly positive and the MACD registers a small buy signal, however the ADX is low which signals limited trend strength and ATR is elevated enough to suggest noticeable intraday movement. OBV points to accumulation, and the classic pivot sits slightly above the market, offering a nearby reference. Technical takeaway: constructive short-term setup within a weak trend — overall buy bias.

All signals

EMA (5 indicators)$18.55 - $24.66
Buy
RSI (14)53.87
Neutral
Stochastic %K (14, 3, 3)83.06
Sell
MACD Level (12, 26)0.06
Buy

Peers & Related Assets

NRIXNurix Therapeutics, Inc.

$25.34-0.7%

CLDXCelldex Therapeutics, Inc.

$29.25+1.0%

GMABGenmab A/S

IMCRImmunocore Holdings plc

NKTRNektar Therapeutics

CGENCompugen Ltd.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.